SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1 PRODUCT IDENTIFIER

Product name:	EN:	Diazepam
	LAT:	Diazepamum
	NL:	Diazepam
	FR:	Diazépam
	DE:	Diazepam
N° CAS:		439-14-5
N° EC:		207-122-5

1.2 RELEVANT IDENTIFIED USES OF THE SUBSTANCE/MIXTURE AND USES ADVISED AGAINST

Identified uses: Active Pharmaceutical Ingredient or Excipient.

1.3 DETAILS OF THE SUPPLIER OF THE SAFETY DATA SHEET

Company: Magis-Pharma NV
Neerlandweg 24
2610 Wilrijk
Belgium

Telephone: (+32) (0)3 457 11 76

Email: info@magis-pharma.be

Web page: www.magis-pharma.be

1.4 EMERGENCY TELEPHONE NUMBER

Public utility foundation:	Belgisch Antigifcentrum	Centre Antipoisons Belge
Telephone:	(+32) (0)70 245 245	(Service 24/7)
Web page:	www.antigifcentrum.be	www.centreantipoisons.be

SECTION 2: HAZARDS IDENTIFICATION

2.1 CLASSIFICATION OF THE SUBSTANCE/MIXTURE

Classification according to (EC) n° 1272/2008

Acute Tox. 3	H301
Acute Tox. 3	H311
Repr. 1B	H360D
Aquatic Chronic 1	H410

2.2 LABEL ELEMENTS

Labelling according to (EC) n° 1272/2008

Hazard pictogram(s):

GHS06 GHS08 GHS09

Signal word(s): Danger

Hazard statements:

H301 Toxic if swallowed

H311	Toxic in contact with skin
H360D	May damage the unborn child.
H410	Very toxic to aquatic life with long lasting effects
Precautionary statements:	
Prevention	
P201	Obtain special instructions before use
P273	Avoid release to the environment
P280	Wear protective gloves/protective clothing/eye protection/face protection.
Response	
P301+P310	
P308 + P313	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
Storage	
P405	IF exposed or concerned: Get medical advice/attention.
	Store locked up
Additional applicable label elements:	Not applicable.

2.3 OTHER HAZARDS

- "The substance is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605."

- "The substance does not meet the criteria for PBT or vPvB in accordance with Annex XIII of Regulation (EC) No 1907/2006."

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 SUBSTANCES

Product name:	Diazepam
IUPAC name:	7-Chloro-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
Synonyms:	Valium
N° CAS:	439-14-5
N° EC:	207-122-5
Molecular Formula:	$C_{16}H_{13}ClN_2O$
Content:	Content: 99.0 per cent to 101.0 per cent (dried substance)

3.2 MIXTURES

Not applicable.

SECTION 4: FIRST AID MEASURES

4.1 DESCRIPTION OF FIRST AID MEASURES

After inhalation:	IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. If symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop, call a physician and be prepared to transport the victim to a hospital. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) should

	be used; if not available, use a level of protection greater than or equal to that advised under « Protective Clothing ».
After skin contact:	IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.
After eye contact:	First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.
After ingestion:	DO NOT INDUCE VOMITING. If the victim is conscious and not convulsing, give 1 or 2 glasses of water to dilute the chemical and IMMEDIATELY call a hospital or poison control center. Be prepared to transport the victim to a hospital if advised by a physician. If the victim is convulsing or unconscious, do not give anything by mouth, ensure that the victim's airway is open and lay the victim on his/her side with the head lower than the body.

4.2 MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED

Symptoms of exposure to this compound may include drowsiness, ataxia, skin rash, dysarthria, nausea, diplopia, anxiety, depression, constipation, changes in salivation, blurred vision, urinary retention, incontinence, tremor, headache, confusion, slurred speech, vertigo, changes in libido and jaundice. Other symptoms of exposure include fatigue, dizziness, respiratory depression, nystagmus, incoordination of the upper extremities, cardiac arrest, hyporeflexia, muscular weakness, agitation, insomnia, grand mal seizures, organic brain syndrome, paradoxical excitement, delirium, coma, hallucinations, vomiting, lethargy and respiratory failure or arrest. It can cause tinnitus, excitability, rage reaction, phlebitis and lactic acidosis. It can also cause central nervous depression, brown discoloration of the lenses, lightheadedness, amnesia, mental depression, blood disorders, dysphoria, slight wheezing, cyanosis, increased respiratory rate, abnormal blood gases, convulsions, increase in chromosomal aberrations, aplastic anemia, leukopenia, leukocytosis, encephalopathy, bilateral gynecomastia, allergic conjunctivitis, angle closure glaucoma, reduction of cardiac output and stroke volume, increase in heart rate and peripheral resistance, cholestasis, disorganization of thought, depressed pupillary response, inhibited performance recall, improved recall of information, reduced reaction time, apprehension, vascular disease, bronchopneumonia, bullous and vesicular skin eruptions, eccrine sweat gland and sweat duct necrosis, skin pallor and death. Exposure can cause decreased blood pressure, increase in hostility and irritability, and vivid or disturbing dreams. Exposure can also lead to hypotension, increased muscle spasticity, sleep disturbances, stimulation, neutropenia, hypoactivity, syncope, bradycardia, urticaria, cardiovascular collapse and hiccups. Damage to the eyes, central nervous system and pulmonary tract may occur. It may also cause dryness of the mouth, aggressive behavior, blood dyscrasias and hepatic dysfunction. If exposure occurs during pregnancy, it may cause lethargy and hypotonia in the offspring. The neonate may also experience apneic attacks. Symptoms may include hypertonia, hyperreflexis, difficulty in sucking, hypothermia and midline cleft deformities of the lip and palate. Depressed central nervous system function may also occur in the neonate.

4.3 INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED

Not available.

SECTION 5: FIREFIGHTING MEASURES

5.1 EXTINGUISHING MEDIA

Suitable extinguishing media:	Fires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher.
Unsuitable extinguishing media:	Not available.

5.2 SPECIAL HAZARDS ARISING FROM THE SUBSTANCE/MIXTURE

When heated to decomposition this compound emits very toxic fumes of chlorine and nitrogen oxides.

5.3 ADVICE FOR FIREFIGHTERS

Surrounding fires:	Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials. ... As with all fires, evacuate personnel to a safe area.
Protection against fire:	Firefighters should use self-contained breathing equipment and protective clothing.
Hazardous combustion products:	Not available.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 PERSONAL PRECAUTIONS, PROTECTIVE EQUIPMENT AND EMERGENCY PROCEDURES

FOR NON-EMERGENCY PERSONNEL

Avoid breathing dust, mists, or vapors. Ensure adequate ventilation.

Wear approved respiratory protection, chemically compatible gloves, and protective clothing (as specified in Section 8).

Keep unprotected personnel away.

FOR EMERGENCY RESPONDERS

Avoid breathing dust, mists, or vapors. Ensure adequate ventilation.

Wear approved respiratory protection, chemically compatible gloves, and protective clothing (as specified in Section 8).

Keep unprotected personnel away.

6.2 ENVIRONMENTAL PRECAUTIONS

P273: Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Do not let product enter drains, surface water, or groundwater.

6.3 METHODS AND MATERIAL FOR CONTAINMENT AND CLEANING UP

P391: Collect spillage.

Wipe up spillage or collect spillage using a high-efficiency particulate air (HEPA) vacuum cleaner. Avoid dry sweeping to prevent dust generation.

Place spillage in an appropriately labeled, tightly closed container for disposal.

Wash and clean the spill site thoroughly with water and a suitable detergent after material pickup is complete.

6.4 REFERENCE TO OTHER SECTIONS

For personal protective equipment, see Section 8.

For waste disposal instructions, see Section 13.

SECTION 7: HANDLING AND STORAGE

7.1 PRECAUTIONS FOR SAFE HANDLING

Precautions for safe handling:	P201: Obtain special instructions before use. P202: Do not handle until all safety precautions have been read and understood. P264: Wash hands and exposed skin thoroughly after handling. P270: Do not eat, drink or smoke when using this product. Avoid all contact with skin, eyes, and clothing. Avoid the generation and inhalation of dust, mists, and/or vapors. Use only under a chemical fume hood or with adequate local exhaust ventilation. Clean equipment and work surfaces thoroughly with a suitable detergent or solvent immediately after use.
Personal protection:	Not available.
Technical protective measures:	This material is combustible. As with all dry organic powders, implement measures to prevent electrostatic discharge. Ground/bond mechanical equipment in contact with dry material to dissipate potential static electricity buildup. Keep away from heat, hot surfaces, sparks, open flames, and other ignition sources.
Handling:	Not available.

7.2 CONDITIONS FOR SAFE STORAGE, INCLUDING ANY INCOMPATIBILITIES

Storage:	Not available.
Conditions for safe storage, including any incompatibilities:	P405: Store locked up. Keep container tightly closed in a dry, cool, and well-ventilated place. Protect from exposure to direct light and moisture. Recommended storage temperature: Ambient (15 – 25°C) or in accordance with the specific manufacturer's certificate of analysis (CoA). Keep away from food, drink, and animal feedingstuffs. Keep out of reach of unauthorized persons. *Incompatible materials:* Strong oxidizing agents.
Storage – away from:	Store protected from light.

7.3 SPECIFIC END USE(S)

Active Pharmaceutical Ingredient or Excipient

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 CONTROL PARAMETERS

Occupational exposure limits:

- Occupational Exposure Band (OEB): OEB 3 / OEB 4 (highly potent Active Pharmaceutical Ingredient).

- Occupational Exposure Limit (OEL): Typically < 100 µg/m³ (8-hour TWA). Consult internal toxicological assessments or facility-specific guidelines.

8.2 EXPOSURE CONTROLS

APPROPRIATE ENGINEERING CONTROL

- Use only in closed systems, containment enclosures (such as glove boxes/isolators), or under a well-functioning chemical fume hood.
- Ensure local exhaust ventilation is equipped with high-efficiency particulate air (HEPA) filtration.
- Maintain eyewash stations and safety showers close to the workstation.

INDIVIDUAL PROTECTION MEASURES

Eye/face protection:	Tightly fitting safety goggles or a face shield conforming to EN 166 are required. Do not wear contact lenses when handling this substance. Approved eye protection is preferred.
Skin protection:	For handling of laboratory scale quantities, a dedicated protective chemical-resistant lab coat or disposable coveralls (e.g., Tyvek) are required. Where significant quantities are handled, specialized work clothing and shoe covers are necessary to prevent take-home contamination.
Hand protection:	- P280: Wear chemically compatible gloves. - Recommended materials: Nitrile rubber or Butyl rubber (minimum thickness of 0.11 mm, breakthrough time > 480 minutes conforming to EN 374). Dispose of contaminated gloves after use. Wash and dry hands.
Respiratory protection:	Where the neat test chemical is weighed and diluted, wear an approved particle respirator type P3 (conforming to EN 143/EN 149) or a respirator equipped with a HEPA filter. An organic vapor cartridge may be added if diluting in organic solvents.
Thermal hazards:	Not available.

ENVIRONMENTAL EXPOSURE CONTROL

- P273: Avoid release to the environment.
- Do not allow substance to enter drains, surface water, or soil. Ensure all exhaust air from ventilation systems passes through appropriate HEPA filtration before release.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1 INFORMATION ON BASIC PHYSICAL AND CHEMICAL PROPERTIES

Physical state:	Solid
Color:	White or almost white
Appearance:	Crystalline powder.
Odour:	Practically odourless.
Melting point/freezing point:	131.5 – 134.5 °C
(Initial) boiling point:	Not available.
Boiling range:	Not available.
Flammability (solid/gas):	Not available.
Flash point:	11 °C
Auto-ignition temperature:	Not available.
Decomposition temperature:	Not available.

pH:	Not available.
Kinematic viscosity:	Not applicable (solid)
Solubility:	Soluble in ethanol (96 per cent).
Solubility in water:	Very slightly soluble in water.
Partition coefficient (n-octanol/water):	LogP 2.82
Upper/lower flammability or explosive limits:	Not available.
Vapour pressure:	Not available.
Density and/or relative density:	1.26 g/cm³
Relative vapour density:	Not available
Particle characteristics:	Not available

9.2 OTHER INFORMATION

9.2.1 Information with regard to physical hazard classes

- Explosive properties: Not available
- Oxidising properties: Not available
- Other physical hazard classes: Not available

9.2.2 Other safety characteristics

Molecular mass: 284.74 g/mol

SECTION 10: STABILITY AND REACTIVITY

10.1 REACTIVITY

Stable under recommended storage conditions.

10.2 CHEMICAL STABILITY

Stable under recommended storage conditions. Protect from light and moisture.

10.3 POSSIBILITY OF HAZARDOUS REACTIONS

No hazardous reactions known under conditions of normal use.

10.4 CONDITIONS TO AVOID

Direct sunlight, static discharge, heat, sparks, open flames, and moisture.

10.5 INCOMPATIBLE MATERIALS

Strong oxidizing agents.

10.6 HAZARDOUS DECOMPOSITION PRODUCTS

In the event of fire, see Section 5.

SECTION 11: TOXICOLOGICAL INFORMATION

11.1 INFORMATION ON TOXICOLOGICAL EFFECTS

Acute toxicity:	- Toxic if swallowed (H301) - Toxic in contact with skin (H311)
Skin corrosion/irritation:	Not available.
Serious eye damage/irritation:	Not available.

Respiratory/skin sensitisation:	Not available.
Germ cell mutagenicity:	Not available.
Carcinogenicity:	There is evidence suggesting a lack of carcinogenicity of diazepam to the breast and inadequate evidence for carcinogenicity at other sites in humans. There is inadequate evidence in experimental animals for the carcinogenicity of diazepam. Overall Evaluation: Diazepam is not classifiable as to its carcinogenicity in humans (Group 3).
Reproductive toxicity:	May damage the unborn child. Classified as Reproductive Toxicant Category 1B (H360D). Exposure during pregnancy is associated with an increased risk of congenital malformations (e.g., cleft palate) and neonatal complications (such as hypotonia, lethargy, and withdrawal symptoms).
Summary of evaluation of the CMR properties:	May damage the unborn child (Repr. 1B). Does not meet the criteria for classification as mutagenic or carcinogenic.
STOT-single exposure:	Not available.
STOT-repeated exposure:	Not available.
Aspiration Hazard:	Not available.
Other:	Symptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.

11.2 ADDITIONAL INFORMATION ON POTENTIAL ADVERSE HUMAN HEALTH EFFECTS AND SYMPTOMS

11.2.1 ENDOCRINE DISRUPTING PROPERTIES

This substance is not identified as having endocrine disrupting properties with respect to human health.

11.2.2 OTHER INFORMATION

Not available.

SECTION 12: ECOLOGICAL INFORMATION

12.1 TOXICITY

Very toxic to aquatic life with long lasting effects (H410).

12.2 PERSISTENCE AND DEGRADABILITY

Not available.

12.3 BIOACCUMULATIVE POTENTIAL

Not available (LogP 2.82 indicates low to moderate bioaccumulation potential).

12.4 MOBILITY IN SOIL

Not available.

12.5 RESULTS OF PBT AND VPVB ASSESSMENT

This substance does not meet the criteria for PBT or vPvB.

12.6 ENDOCRINE DISRUPTING PROPERTIES

This substance is not identified as having endocrine disrupting properties with respect to non-target organisms in the environment in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605.

12.7 OTHER ADVERSE EFFECTS

Not available.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1 WASTE TREATMENT METHODS

- P501: Dispose of contents/container to an approved waste disposal plant in accordance with local, regional, national, and international regulations.
- Expired or waste pharmaceuticals must be treated as hazardous chemical/medical waste.
- It is strictly prohibited to dispose of this material by flushing it down the toilet, discarding it into domestic trash, or releasing it into the sewage system or the environment.
- Waste must be collected, labeled, and securely packaged in accordance with European waste regulations (such as the European Waste Catalogue - EWC).
- Alternatively, the waste pharmaceutical shall be handled and transported by a licensed hazardous waste contractor for high-temperature incineration at an approved facility. Contaminated packaging must be treated in the same manner as the active substance itself.

SECTION 14: TRANSPORT INFORMATION

Transport information according to ADR/RID/IMDG/ICAO/IATA

14.1 UN NUMBER

ADR/ RID(Land),IMDG(Sea), IATA/ICAO (Air) : UN2811

14.2 UN PROPER SHIPPING NAME

ADR/ RID(Land),IMDG(Sea), IATA/ICAO (Air) : TOXIC SOLID, ORGANIC, N.O.S.

14.3 TRANSPORT HAZARD CLASS(ES)

ADR/ RID(Land),IMDG(Sea), IATA/ICAO (Air) : 6.1

14.4 PACKING GROUP

ADR/ RID(Land),IMDG(Sea), IATA/ICAO (Air) : III

14.5 ENVIRONMENTAL HAZARDS

ADR/ RID(Land),IMDG(Sea), IATA/ICAO (Air) : Yes (Marine Pollutant / Environmentally Hazardous Substance)

14.6 SPECIAL PRECAUTIONS FOR USER

Refer to Section 6, 7 and 8. Keep away from food and drink.

14.7 MARITIME TRANSPORT IN BULK ACCORDING TO IMO INSTRUMENTS

Not applicable.

14.8 ADDITIONAL TRANSPORT INFORMATION

Not available.

SECTION 15: REGULATORY INFORMATION

15.1 SAFETY, HEALTH AND ENVIRONMENTAL REGULATIONS/LEGISLATION SPECIFIC FOR THE SUBSTANCE/MIXTURE

EU Regulations:

- *Regulation (EC) No 1272/2008 (CLP):* This substance is classified and labeled in accordance with the CLP Regulation. (See Section 2.2 for Hazard Pictograms, Signal Word, H-statements, and P-statements).

- *Regulation (EC) No 1907/2006 (REACH):*
  - Annex XIV (Authorization List): This substance is not listed.
  - Annex XVII (Restrictions on manufacture, placing on the market and use): Restricted to professional users. Refer to Entry 28/29/30 (toxic for reproduction).

- *Directive 2012/18/EU (Seveso III):* Not applicable (or check facility-specific storage thresholds for toxic/environmental hazards).

National Regulations (Belgium):

- Royal Decree of 12 April 1974 (Regulating certain psychotropic substances): Diazepam is a strictly controlled substance in Belgium. Possession, manufacture, trade, and use are subject to strict authorization, record-keeping, and licensing requirements by the FAMHP (Federal Agency for Medicines and Health Products / FAGG).

- Belgian Codex on Well-being at Work (Codex over het welzijn op het werk): Measures for protection of workers from chemical agents (Title 1 of Book VI) and provisions for pregnant/breastfeeding workers (due to Repr. 1B classification) must be strictly implemented.

15.2 CHEMICAL SAFETY ASSESSMENT

A Chemical Safety Assessment (CSA) has not been carried out for this substance by the supplier.

SECTION 16: OTHER INFORMATION

16.1 CHANGES SINCE THE PREVIOUS VERSION

- Document updated to comply with Regulation (EU) 2020/878.
- Classification and precautionary statements aligned with Regulation (EC) No 1272/2008 (CLP).
- Removed outdated R- and S-phrases.

16.2 ABBREVIATIONS AND ACRONYMS USED

ADR:	European Agreement concerning the International Carriage of Dangerous Goods by Road
CAS:	Chemical Abstracts Service (division of the American Chemical Society)
CLP:	Classification, Labelling and Packaging Regulation (EC) No 1272/2008
EC (number):	European Community (number)
ECHA:	European Chemicals Agency
FAMHP:	Federal Agency for Medicines and Health Products (FAGG, Belgium)
GHS:	Globally Harmonized System of Classification and Labelling of Chemicals
IATA:	International Air Transport Association
ICAO:	International Civil Aviation Organization
IMDG:	International Maritime Code for Dangerous Goods

IUPAC:	International Union of Pure and Applied Chemistry
OEL:	Occupational Exposure Limit
PBT:	Persistent, Bioaccumulative and Toxic substance
REACH:	Registration, Evaluation, Authorisation and Restriction of Chemicals Regulation (EC) No 1907/2006
RID:	Regulations Concerning the International Transport of Dangerous Goods by Rail
STOT:	Specific Target Organ Toxicity
UN (number):	United Nations (number)
vPvB:	very Persistent and very Bioaccumalative

16.3 KEY LITERATURE REFERENCES/SOURCES FOR DATA

- European Chemicals Agency (ECHA): https://www.echa.europa.eu/
- ECHA C&L Inventory: https://echa.europa.eu/information-on-chemicals/cl-inventory-database
- Belgian Federal Agency for Medicines and Health Products (FAMHP) guidelines.

16.4 METHOD OF CLASSIFICATION IN CASE OF MIXTURE

Not applicable.

16.5 RELEVANT HAZARD STATEMENTS AND/OR PRECAUTIONARY STATEMENTS

Full text of H-Statements referred to under Sections 2 and 3:

H301: Toxic if swallowed.
H311: Toxic in contact with skin.
H360D: May damage the unborn child.
H410: Very toxic to aquatic life with long lasting effects.

Full text of P-Statements referred to under Sections 2 to 15:

P201: Obtain special instructions before use.
P202: Do not handle until all safety precautions have been read and understood.
P264: Wash hands and exposed skin thoroughly after handling.
P270: Do not eat, drink or smoke when using this product.
P273: Avoid release to the environment.
P280: Wear protective gloves/protective clothing/eye protection/face protection.
P301 + P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P308 + P313: IF exposed or concerned: Get medical advice/attention.
P330: Rinse mouth.
P391: Collect spillage.
P405: Store locked up.
P501: Dispose of contents/container to an approved waste disposal plant.

16.6 TRAINING ADVISEMENT

- Workers handling this active pharmaceutical ingredient must be trained on the specific occupational hazards of potent active substances, proper use of personal protective equipment (PPE), containment procedures, and emergency response actions for toxic materials.

- Due to the reprotoxic classification (H360D), female workers of childbearing potential must be fully informed of the risks and appropriate safety protocols.

16.7 NOTICE FOR USER(S)

The information provided in this MSDS has been established in accordance with Commission Regulation (EU) 2020/878, amending Annex II to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH).

This MSDS is intended to provide a brief summary of our knowledge and guidance regarding the use of this material. The information has been compiled from sources considered to be dependable and is accurate to the best of Magis-Pharma NV's knowledge. However, the information is provided without any representation or warranty, expressed or implied regarding its accuracy or correctness. Magis-Pharma NV cannot assume responsibility for adverse events which may occur in the use and/or misuse of this product and expressly disclaims liability for loss, damage and/or expense arising out of or in any way connected with the handling, storage, use and/or disposal of this product.

16.8 DEPARTMENT ISSUING MSDS

Magis-Pharma NV
info@magis-pharma.be